SC
BBIO icon

Shay Capital’s BridgeBio Pharma BBIO Stock Holding History

Shay Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,600
Closed -$371K – 422
2025
Q2 		$371K Buy
+8,600
New +$313K 0.04% 204
2023
Q2 		– Sell
-7,300
Closed -$110K – 417
2023
Q1 		$121K Buy
+7,300
New +$85.1K 0.02% 326

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shay Capital's BBIO Position: Q3 2025 in Review

Shay Capital sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 8,600 shares — an estimated $371K sold.

Shay Capital first reported a position in BBIO in Q1 2023 and held it in 2 quarters. The position peaked at $371K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Shay Capital reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • Shay Capital sold 8,600 BridgeBio Pharma shares in Q3 2025, an estimated $371K.
  • Shay Capital first reported a position in BridgeBio Pharma in Q1 2023 and held it in 2 quarters.
  • Shay Capital's BridgeBio Pharma position peaked at $371K in Q2 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Shay Capital's 13F filing for Q3 2025, filed 14 Nov 2025.